<DOC>
	<DOCNO>NCT01583361</DOCNO>
	<brief_summary>This randomize , multicenter , control trial prove efficacy S‐1 Oxaliplatin Neoadjuvant Chemotherapy Advanced Gastric Cancer Patients undergo D2 gastrectomy . The primary endpoint three-year free disease second primary include five-year overall survival , safety R0 resection rate .</brief_summary>
	<brief_title>SOX Regimen Neoadjuvant Chemotherapy AJCC Stage II-III Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologically confirm gastric adenocarcinoma 2 . Gastroesophageal junction tumour type II III ( NCCN 2009 ) enrol 3 . All patient must undergo EUS , CT ( PETCT ) laparoscopy evaluate tumor stage classification ( TNM ) , stage II III ( AJCC 7th ) gastric cancer patient enrol 4. planning undergo gastric cancer D2 surgery neoadjuvant chemotherapy 5 . KPS &gt; 60 ; ECOG performance status 02 6 . Life expectancy &gt; 6 month 7 . Age : 20 75 year 8 . No severe disease life expectancy less five year 9 . 7 day enrol , baseline data finish include : Granulocyte count ≥ 1.5×109/L ; platelet count ≥ 100×109/L ; Hemoglobin ≥ 90g/L ; hepatic &lt; 1.5×ULN ; total bilirubin ≤ 1.0×ULN ; creatinine &lt; 1.5×ULN ; PTINR/PTT &lt; 1.7× ULN 10 . Disease measurable Response Evaluation Criteria Solid Tumors ( RECIST1.1 ) criteria 11 . Written inform consent able comply protocol 1 . Patient undergo surgery chemotherapy severe disease 2 . Be allergic chemotherapy drug 3 . Patients receive chemotherapy drug involve trial four week enrol 4 . Patients receive cytotoxic chemotherapy , target therapy , immunotherapy radiotherapy gastric cancer 5 . Within last 5 year patient history malignant diseases 6 . Pregnant breastfeed woman 7 . Severe heart disease like symptom coronary heart disease , New York Heart Association ( NYHA ) grade II worse congestive heart failure cardiac arrhythmia medication myocardial infarction within last 12 month 8 . Patients upper gastrointestinal obstruction absorption anomaly ; patient obstruction Helicobacter pylori failure like effect S1 take absorb 9 . Patients history peripheral nerve disease 10 . Patients get organ transplant 11. lack dihydropyrimidine dehydrogenase ( DPD ) 12 . Infection disease failure control</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>two arm</keyword>
	<keyword>D2 lymphadenectomy</keyword>
	<keyword>chemotherapy surgery</keyword>
	<keyword>disease free survival</keyword>
</DOC>